scispace - formally typeset
A

Axel Ullrich

Researcher at Max Planck Society

Publications -  436
Citations -  63142

Axel Ullrich is an academic researcher from Max Planck Society. The author has contributed to research in topics: Receptor tyrosine kinase & Tyrosine kinase. The author has an hindex of 124, co-authored 436 publications receiving 61445 citations. Previous affiliations of Axel Ullrich include Institute of Molecular and Cell Biology & Agency for Science, Technology and Research.

Papers
More filters
Book ChapterDOI

- EGFR: EGF receptor (vertebrates) (c-erbB)

Klaus Seedorf, +1 more
TL;DR: The chapter describes the EGFR that is the high-affinity receptor for epidermal growth factor (EGF), transforming growth factor-a (TGFa), and VGF, and its homologues have been identified in Caenorhabditis elegans and Xiphophorus.
Patent

Fgfr4 favorise la résistance des cellules cancéreuses en réponse aux médicaments chimiothérapiques

Axel Ullrich, +2 more
TL;DR: La presente invention concerne des inhibiteurs du recepteur du facteur de croissance des fibroblastes 4 co-administres avec une procedure et/ou un agent therapeutique destines a prevenir, soulager and/ou traiter une affection hyper-proliferative, par exemple un cancer tel qu'un cancer resistant a la chimiotherapie.
Book ChapterDOI

- CSF1R: CSF-1 receptor (vertebrates) (Macrophage-CSF receptor1, c-fms gene product2)

Ronald Herbst, +1 more
TL;DR: CSF1R is a receptor PTK that is required for proliferation and survival of monocytes, macrophages, and committed bone marrow progenitors and covalently modified forms of the receptor are selectively internalized.
Patent

GRK5 Kinases as targets for anti-diabetic therapy

Falcenberg Mathias, +1 more
TL;DR: In this article, a compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression or release of insulin was proposed, which is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism.
Patent

Inhibitory anti-HER3 antibody for sensitizing melanoma metastases or refactory melanoma for treatment with chemotherapeeutic agents or radiation therapy

Axel Ullrich, +2 more
TL;DR: In this article, an inhibitor of HER3 for the treatment of melanoma, pharmaceutical compositions comprising such an inhibitor and a method for the diagnosis or prognosis for melanoma was presented.